Oncology Institute Inc
TOI3.380USD
-0.010-0.29%
Market hours （ET）Quotes delayed by 15 min
329.79MMarket Cap
LossP/E TTM
More Details of Oncology Institute Inc Company
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
Oncology Institute Inc Info
Ticker SymbolTOI
Company nameOncology Institute Inc
IPO dateMar 13, 2020
CEOVirnich (Daniel)
Number of employees825
Security typeOrdinary Share
Fiscal year-endMar 13
Address18000 Studebaker Rd
CityCERRITOS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code90703
Phone15627353226
Websitehttps://theoncologyinstitute.com/
Ticker SymbolTOI
IPO dateMar 13, 2020
CEOVirnich (Daniel)
Company Executives of Oncology Institute Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
+1.07%
Mr. Brad Hively
Mr. Brad Hively
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
712.03K
+51.10%
Ms. Anne Mcgeorge
Ms. Anne Mcgeorge
Independent Chairman of the Board
Independent Chairman of the Board
291.37K
+58.92%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
289.09K
+45.97%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.37K
+0.08%
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
196.63K
+1.86%
Ms. Kristin England
Ms. Kristin England
Chief Administrative Officer
Chief Administrative Officer
98.04K
--
Mr. Mark L. Pacala
Mr. Mark L. Pacala
Independent Director
Independent Director
--
--
Ms. Karen M. Johnson
Ms. Karen M. Johnson
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
+1.07%
Mr. Brad Hively
Mr. Brad Hively
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
712.03K
+51.10%
Ms. Anne Mcgeorge
Ms. Anne Mcgeorge
Independent Chairman of the Board
Independent Chairman of the Board
291.37K
+58.92%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
289.09K
+45.97%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.37K
+0.08%
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
196.63K
+1.86%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
By BusinessUSD
Name
Revenue
Proportion
Dispensary revenue
62.57M
52.23%
FFS revenue
37.05M
30.92%
Capitated revenue
18.84M
15.73%
Clinical research trials and other revenue
1.34M
1.12%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Dispensary revenue
62.57M
52.23%
FFS revenue
37.05M
30.92%
Capitated revenue
18.84M
15.73%
Clinical research trials and other revenue
1.34M
1.12%
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
M33 Growth LLC
5.53%
The Vanguard Group, Inc.
4.62%
OncologyCare Partners LLC
4.18%
Deerfield Management Company, L.P.
3.42%
BlackRock Institutional Trust Company, N.A.
3.17%
Other
79.09%
Shareholders
Shareholders
Proportion
M33 Growth LLC
5.53%
The Vanguard Group, Inc.
4.62%
OncologyCare Partners LLC
4.18%
Deerfield Management Company, L.P.
3.42%
BlackRock Institutional Trust Company, N.A.
3.17%
Other
79.09%
Shareholder Types
Shareholders
Proportion
Investment Advisor
12.34%
Hedge Fund
11.00%
Investment Advisor/Hedge Fund
10.03%
Venture Capital
5.53%
Individual Investor
4.89%
Corporation
4.18%
Research Firm
0.92%
Private Equity
0.26%
Bank and Trust
0.17%
Other
50.68%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
145
39.72M
42.48%
-7.79M
2025Q2
119
39.72M
44.51%
-19.63M
2025Q1
137
46.36M
52.04%
-13.47M
2024Q4
138
45.05M
59.62%
-19.81M
2024Q3
139
50.89M
67.39%
-11.59M
2024Q2
143
57.80M
76.77%
-3.05M
2024Q1
146
56.10M
75.87%
-3.90M
2023Q4
143
57.48M
77.79%
-4.30M
2023Q3
176
58.70M
79.97%
-14.73M
2023Q2
180
58.28M
81.90%
-25.39M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
M33 Growth LLC
8.52M
9.12%
-5.15M
-37.65%
Sep 04, 2025
The Vanguard Group, Inc.
4.28M
4.58%
+2.53M
+144.52%
Jun 30, 2025
OncologyCare Partners LLC
4.11M
4.4%
--
--
Mar 26, 2025
Deerfield Management Company, L.P.
3.36M
3.59%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.00M
3.2%
+2.74M
+1088.12%
Jun 30, 2025
CenterBook Partners LP
715.90K
0.77%
+715.90K
--
Jun 30, 2025
Balyasny Asset Management LP
2.52M
2.69%
+371.00K
+17.28%
Jun 30, 2025
Wexford Capital LP
1.12M
1.2%
+1.12M
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.28M
1.37%
+893.70K
+231.68%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Vanguard US Momentum Factor ETF
0.11%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Vanguard US Momentum Factor ETF
Proportion0.11%
iShares Micro-Cap ETF
Proportion0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.03%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Oncology Institute Inc?
The top five shareholders of Oncology Institute Inc are:
M33 Growth LLC holds 8.52M shares, accounting for 9.12% of the total shares.
The Vanguard Group, Inc. holds 4.28M shares, accounting for 4.58% of the total shares.
OncologyCare Partners LLC holds 4.11M shares, accounting for 4.40% of the total shares.
Deerfield Management Company, L.P. holds 3.36M shares, accounting for 3.59% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.00M shares, accounting for 3.20% of the total shares.
M33 Growth LLC holds 8.52M shares, accounting for 9.12% of the total shares.
The Vanguard Group, Inc. holds 4.28M shares, accounting for 4.58% of the total shares.
OncologyCare Partners LLC holds 4.11M shares, accounting for 4.40% of the total shares.
Deerfield Management Company, L.P. holds 3.36M shares, accounting for 3.59% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.00M shares, accounting for 3.20% of the total shares.
What are the top three shareholder types of Oncology Institute Inc?
The top three shareholder types of Oncology Institute Inc are:
M33 Growth LLC
The Vanguard Group, Inc.
OncologyCare Partners LLC
M33 Growth LLC
The Vanguard Group, Inc.
OncologyCare Partners LLC
How many institutions hold shares of Oncology Institute Inc (TOI)?
As of 2025Q3, 145 institutions hold shares of Oncology Institute Inc, with a combined market value of approximately 39.72M, accounting for 42.48% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -2.03%.
What is the biggest source of revenue for Oncology Institute Inc?
In FY2025Q2, the Dispensary revenue business generated the highest revenue for Oncology Institute Inc, amounting to 62.57M and accounting for 52.23% of total revenue.
